Supplemental material
Acta Oncologica
Volume 60, 2021 - Issue 12
ORIGINAL ARTICLES: CLINICAL ONCOLOGY
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
, , , , , , 
, , , & show all
Bjørn Henning Grønbergi Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway;j Department of Oncology, St. Olav’s Hospital, Trondheim University Hospital, Trondheim, Norwayhttps://orcid.org/0000-0001-5744-1534View further author information
https://orcid.org/0000-0001-5744-1534View further author information, , , & Odd Terje Brustuguna Section of Oncology, Vestre Viken Hospital Trust, Drammen, Norway;b Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norwayhttps://orcid.org/0000-0002-5153-8391View further author information
https://orcid.org/0000-0002-5153-8391View further author information show allReprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Source:
Taylor & Francis
Linking provided by
